Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Stock Short Interest Climbs 74.6%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 7,209 shares, an increase of 74.6% from the September 15th total of 4,130 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 7,501 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A hedge fund recently bought a new stake in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC acquired a new position in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned 0.62% of Fidelity Disruptive Medicine ETF at the end of the most recent quarter.

Fidelity Disruptive Medicine ETF Trading Up 1.7%

Fidelity Disruptive Medicine ETF stock traded up $0.52 during midday trading on Thursday, reaching $31.16. 2,525 shares of the stock traded hands, compared to its average volume of 10,407. Fidelity Disruptive Medicine ETF has a fifty-two week low of $23.48 and a fifty-two week high of $32.99. The firm has a market cap of $49.85 million, a price-to-earnings ratio of 41.33 and a beta of 0.76. The firm has a fifty day moving average price of $31.47 and a two-hundred day moving average price of $28.12.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.